Does Placenta Pathology Predict Outcome of Neonates With Hypoxic Ischemic Encephalopathy?"

The histology of the placenta of newborn infants with perinatal asphyxia and hypoxic-ischaemic encephalopathy is analysed. There will be an evaluation if placenta could be a biomarker for neurodevelopmental outcome at 18-24 months of age.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asphyxia Neonatorum Congenital, Hereditary, and Neonatal Diseases and Abnormalities Infant, Newborn, Diseases

Age range

1 day–4 day

Sex eligibility

All sexes

Study type

Observational

Primary location

University Children's hospital Zurich

Zurich, 8044, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all newborn infants with APGAR <5 at 10minutes, pH<7.0, lactate >12mmol/L, base excess >16, resuscitation >10min after birth, gestational age >35 weeks and an encephalopathy -

Exclusion criteria

Treatment and study plan

hypothermia therapy

Other

newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).

Primary outcomes

neurodevelopmental outcome at 18-24 month of Age

Time frame: 7 years

The investigators will analyse if there is a correlation of placenta histology and neurodevelopmental outcome

Sponsors and collaborators

Lead sponsor

University Children's Hospital, Zurich

Other

Registry information

Important dates

Study start: 2011
Primary completion: 2017
Study completion: 2017
First posted: Sep 15, 2017
Registry last updated: Sep 21, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed